|
시장보고서
상품코드
2016440
항감염제 시장 보고서 : 유형, 투여 경로, 유통 채널, 지역별(2026-2034년)Anti-infectives Market Report by Type, Route of Administration (Topical, Oral, Intravenous, and Others), Distribution Channel, and Region 2026-2034 |
||||||
세계의 항감염제 시장 규모는 2025년에 1,429억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 1,829억 달러에 달하며, 2026-2034년에 CAGR 2.70%로 성장할 것으로 예측하고 있습니다.
항감염제는 감염원의 확산을 억제하거나 감염원을 직접 사멸시킴으로써 감염에 대항하는 작용을 하는 의약품입니다. 이러한 의약품에는 항생제, 항바이러스제, 항진균제, 항말라리아제, 구충제, 항원충제 등이 포함됩니다. 일반적으로 경구, 비경구, 외용 등의 경로로 투여됩니다. 이들은 폐렴이나 결핵과 같은 경미한 감염성 질환의 치료에 널리 사용되고 있습니다. 이 외에도 항감염제는 심각한 감염 위험이 높은 제왕절개, 인공관절 치환술과 같은 일상적인 시술이나 수술 시에도 사용되고 있습니다.
항감염제 시장 동향:
세계의 항감염증 치료제 시장은 주로 전 세계에서 증가하는 감염증의 발생률에 의해 주도되고 있습니다. 항감염제는 바이러스, 세균, 기생충, 곰팡이 등의 감염성 질환을 치료하는 데 사용됩니다. 또한 천연물, 쿼람센싱 억제제, 바이오필름 파괴제, 갈륨계 약물, 사이클로덱스트린 억제제, 빛을 이용한 항균제 등 다양한 전략으로 개발된 신규 약물들이 시장 성장을 촉진하고 있습니다. 이에 따라 신약 개발 과정의 최신 혁신 기술인 줄기세포와 OOC(Organ-on-a-Chip) 기술 등 신약 개발 과정을 강화하기 위한 최신 혁신이 시장에 밝은 전망을 제시하고 있습니다. 또한 COVID-19의 유행과 이에 따른 아스페르길루스증, 침습성 칸디다증, 뮤코다증 등 감염성 질환의 증가로 인한 제품 채택 확대가 시장 성장을 촉진하고 있습니다. 이와 더불어, 규제 당국의 신규 항감염제 승인 건수 증가도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 또한 정부의 지원책 시행, 혁신 신약 개발에 대한 투자 확대, 감염병에 대한 개인의 인식 개선, 그리고 빠르게 발전하고 있는 헬스케어 인프라 구축은 향후 수년간 시장 성장을 촉진할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 항감염제 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSA 26.05.07The global anti-infectives market size reached USD 142.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 182.9 Billion by 2034, exhibiting a growth rate (CAGR) of 2.70% during 2026-2034.
Anti-infectives are medicines that act against infections, either by inhibiting the spread or killing the infectious agent outright. These medicines include antibiotics, antivirals, antifungals, antimalarials, anthelmintics, and antiprotozoals. They are generally administered through oral, parenteral, and topical routes. They are widely used to treat minor infectious diseases, including pneumonia and tuberculosis. Apart from this, anti-infectives are also utilized during routine procedures and surgeries, such as cesarian section and joint replacement, which are associated with a high risk of severe infection.
ANTI-INFECTIVES MARKET TRENDS:
The global anti-infectives market is primarily driven by rising incidences of infectious diseases across the globe. Anti-Infinitives are used to treat infections, including viruses, bacteria, parasites, and fungi. Additionally, the development of novel drugs that are formulated using different strategies, such as natural products, quorum sensing inhibitors, biofilm disruptors, gallium-based drugs, cyclodextrin inhibitors, and light-based antimicrobials, are providing an impetus to the market growth. In line with this, the latest innovations in drug discovery procedures, such as stem cells and organ-on-chip (OOC) technologies, to enhance drug trial processes are creating a positive outlook for the market. Furthermore, the increasing product adoption due to the advent of the COVID-19 disease and induced infections, such as aspergillosis, invasive candidiasis, and mucormycosis, is strengthening the growth of the market. Besides this, the increasing number of new anti-infective drugs being approved by the regulatory authorities is acting as another growth-inducing factor. Moreover, the implementation of favorable government policies, rising investments in developing new and innovative drugs, increasing awareness among individuals about infectious diseases, and rapidly improving healthcare infrastructure are anticipated to impel the growth of the market in the coming years.
KEY MARKET SEGMENTATION:
Breakup by Type:
- Antibacterial
- Antifungal
- Antiviral
Breakup by Route of Administration:
- Topical
- Oral
- Intravenous (IV)
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Speciality Pharmacies
- Online Stores
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The report provides a comprehensive analysis of the competitive landscape in the global anti-infectives market with detailed profiles of all major companies, including:
- Abbott Laboratories
- Cipla Health
- F. Hoffmann-La Roche Ltd
- Fresenius SE & Co. KGaA
- Glenmark Pharmaceuticals Limited
- GSK plc
- Lupin Limited
- Mankind Pharma Limited
- Sandoz Inc.
- Sun Pharmaceutical Industries Ltd.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global anti-infectives market in 2025?
2. What is the expected growth rate of the global anti-infectives market during 2026-2034?
3. What are the key factors driving the global anti-infectives market?
4. What has been the impact of COVID-19 on the global anti-infectives market?
5. What is the breakup of the global anti-infectives market based on the type?
6. What is the breakup of the global anti-infectives market based on the route of administration?
7. What is the breakup of the global anti-infectives market based on distribution channel?
8. What are the key regions in the global anti-infectives market?
9. Who are the key players/companies in the global anti-infectives market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Anti-infectives Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Antibacterial
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Antifungal
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Antiviral
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Topical
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Oral
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Intravenous (IV)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Speciality Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Online Stores
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Cipla Health
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 F. Hoffmann-La Roche Ltd
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.4 Fresenius SE & Co. KGaA
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Glenmark Pharmaceuticals Limited
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 GSK plc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Lupin Limited
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Mankind Pharma Limited
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Sandoz Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 Sun Pharmaceutical Industries Ltd.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.1 Abbott Laboratories
